Open source drug discovery- A new paradigm of collaborative research in tuberculosis drug development

被引:51
作者
Bhardwaj, Anshu [1 ]
Scaria, Vinod [2 ]
Raghava, Gajendra Pal Singh [3 ]
Lynn, Andrew Michael [4 ]
Chandra, Nagasuma [5 ]
Banerjee, Sulagna [6 ]
Raghunandanan, Muthukurussi V. [2 ]
Pandey, Vikas [2 ]
Taneja, Bhupesh [2 ]
Yadav, Jyoti [2 ]
Dash, Debasis [2 ]
Bhattacharya, Jaijit [7 ]
Misra, Amit [8 ]
Kumar, Anil [9 ]
Ramachandran, Srinivasan [2 ]
Thomas, Zakir [1 ]
Brahmachari, Samir K. [1 ,2 ]
机构
[1] CSIR, New Delhi 110001, India
[2] CSIR, Inst Genom & Integrat Biol, Delhi 110007, India
[3] CSIR, Inst Microbial Technol, Sect 39A, Chandigarh 160036, India
[4] Jawaharlal Nehru Univ, Sch Informat Technol, New Delhi 110067, India
[5] Indian Inst Sci, Bioinformat Ctr, Bangalore 560012, Karnataka, India
[6] Anna Univ, KB Chandrasekhar Ctr, Madras 600044, Tamil Nadu, India
[7] Hewlett Packard Corp, Gurgaon 122002, India
[8] CSIR, Cent Drug Res Inst, Lucknow 226001, Uttar Pradesh, India
[9] Sri Sathya Sai Univ, Dept Chem, Prashanti Nilayam 515134, India
关键词
Open source; Drug Discovery; Tuberculosis; Malaria; Neglected diseases; Generics; MYCOBACTERIUM-TUBERCULOSIS;
D O I
10.1016/j.tube.2011.06.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It is being realized that the traditional closed-door and market driven approaches for drug discovery may not be the best suited model for the diseases of the developing world such as tuberculosis and malaria, because most patients suffering from these diseases have poor paying capacity. To ensure that new drugs are created for patients suffering from these diseases, it is necessary to formulate an alternate paradigm of drug discovery process. The current model constrained by limitations for collaboration and for sharing of resources with confidentiality hampers the opportunities for bringing expertise from diverse fields. These limitations hinder the possibilities of lowering the cost of drug discovery. The Open Source Drug Discovery project initiated by Council of Scientific and Industrial Research, India has adopted an open source model to power wide participation across geographical borders. Open Source Drug Discovery emphasizes integrative science through collaboration, open-sharing, taking up multi-faceted approaches and accruing benefits from advances on different fronts of new drug discovery. Because the open source model is based on community participation, it has the potential to self-sustain continuous development by generating a storehouse of alternatives towards continued pursuit for new drug discovery. Since the inventions are community generated, the new chemical entities developed by Open Source Drug Discovery will be taken up for clinical trial in a non-exclusive manner by participation of multiple companies with majority funding from Open Source Drug Discovery. This will ensure availability of drugs through a lower cost community driven drug discovery process for diseases afflicting people with poor paying capacity. Hopefully what LINUX the World Wide Web have done for the information technology, Open Source Drug Discovery will do for drug discovery. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:479 / 486
页数:8
相关论文
共 24 条
[1]  
Anurag M, 2009, MOL BIOSYST, V5, P1752, DOI [10.1039/b905518p, 10.1039/B905518p]
[2]   Mechanistic and functional insights into fatty acid activation in Mycobacterium tuberculosis [J].
Arora, Pooja ;
Goyal, Aneesh ;
Natarajan, Vivek T. ;
Rajakumara, Eerappa ;
Verma, Priyanka ;
Gupta, Radhika ;
Yousuf, Malikmohamed ;
Trivedi, Omita A. ;
Mohanty, Debasisa ;
Tyagi, Anil ;
Sankaranarayanan, Rajan ;
Gokhale, Rajesh S. .
NATURE CHEMICAL BIOLOGY, 2009, 5 (03) :166-173
[3]  
BHARDWAJ A, 2011, COLLABORATIVE COMPUT, P321
[4]   TBrowse: An integrative genomics map of Mycobacterium tuberculosis [J].
Bhardwaj, Anshu ;
Bhartiya, Deeksha ;
Kumar, Nitin ;
Scaria, Vinod .
TUBERCULOSIS, 2009, 89 (05) :386-387
[5]   Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs [J].
Budha, Nageshwar R. ;
Lee, Richard E. ;
Meibohm, Bernd .
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (08) :809-825
[6]   New approaches to filling the gap in tuberculosis drug discovery [J].
Casenghi, Martina ;
Cole, Stewart T. ;
Nathan, Carl F. .
PLOS MEDICINE, 2007, 4 (11) :1722-1725
[7]   Multildrug-resistant and extensively drug-resistant tuberculosis: a review [J].
Chan, Edward D. ;
Iseman, Michael D. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2008, 21 (06) :587-595
[8]  
Johnston JM, 2005, ACTA CRYSTALLOGR D, V61, P1199, DOI [10.1107/s0907444905017531, 10.1107/S0904777905017531]
[9]  
KAK A, 2010, EXPRESS PHARM, V5, P30
[10]   Can Open-Source Drug R&D Repower Pharmaceutical Innovation? [J].
Munos, B. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) :534-536